Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | SDHA | P31040 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163012 | 0.85 | MAOA (0.48) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL10162812 | 0.85 | MAOA (0.48) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9951426 | 0.85 | MAOA (0.48) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL10163011 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9950929 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9951346 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL10161317 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9950934 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9951282 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA | |
| SCHEMBL9951343 | 0.83 | MAOA (0.47) | F10MAOAMAOBPTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| WO-2010150281-A2 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | F10 2700/4885MAOA 673/4885MAOB 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.